Pulmatrix, Inc. — fact timeline

Pulmatrix, Inc. reported financial results for first fiscal quarter ended March 31, 2026.

“Pulmatrix, Inc. issued a press release announcing its financial results for the first fiscal quarter ended March 31, 2026”

Pulmatrix, Inc. terminated Agreement and Plan of Merger and Reorganization with Cullgen Inc. (effective 2026-02-28).

“Pulmatrix, Inc. (the “ Company ” or “ Pulmatrix ”) received a termination notice (the “ Notice ”) from Cullgen Inc. (“ Cullgen ”) pursuant to which Cullgen informed the Company that in accordance with Sections 11.7 and 10.1(b) of that certain Agreement and Plan of Merger and Reorganization, dated as of November 13, 2024, as amended by Amendment No. 1 thereto dated as of April 7, 2025 (the “ Merger Agreement ”), by and among the Company, Pulmatrix and PCL Merger Sub, Inc. and PCL Merger Sub Inc. II, LLC, Cullgen was terminating the Merger Agreement and all related transactions thereunder.”

Pulmatrix, Inc.: Revised voting standards language in Article I, Section 7 of the Bylaws via Amendment No. 2 (effective 2025-02-11).

“On February 11, 2025, the board of directors of Pulmatrix, Inc. (the “Company”) approved Amendment No. 2 (the “Amendment”) to the Restated Bylaws of the Company, as amended (the “Bylaws”), effective as of February 11, 2025. The Amendment amends and restates Article I, Section 7 of the Bylaws in its entirety to revise the voting standards language.”

Peter Ludlum was appointed as Interim Chief Executive Officer at Pulmatrix, Inc..

“the Board approved the appointment of Peter Ludlum as the Interim Chief Executive Officer (the “Interim CEO”), effective as of July 20, 2024”

Teofilo Raad departed as Chief Executive Officer at Pulmatrix, Inc..

“Effective as of the Separation Date, Mr. Raad’s employment with the Company shall cease and Mr. Raad shall relinquish all positions, offices, and authority with the Company and any affiliates, including as a member of the Board”

Pulmatrix, Inc. reported three months ended March 31, 2024 results: revenue $5.9 million, net income $0.8 million.

“outside the United States. Within the United States, Pulmatrix and Cipla will seek to monetize PUR1900. First Quarter 2024 Financial Results Revenues increased $4.4 million to $5.9 million for the three months ended March 31, 2024, compared to $1.5 million for the three months ended March 31, 2023. The increase is primarily related to a contract modification of the”

Pulmatrix, Inc. reported the year ended December 31, 2023 results: revenue $7.3 million.

“Revenues increased $1.2 million to $7.3 million for the year ended December 31, 2023, compared to $6.1 million for the year ended December 31, 2022.”

Dr. Margaret Wasilewski was terminated as Chief Medical Officer at Pulmatrix, Inc..

“On March 7, 2024, the Board of Directors of Pulmatrix, Inc. (the “Company”) approved the termination of the Company’s Chief Medical Officer (“CMO”), Dr. Margaret Wasilewski’s, employment with the Company.”

Pulmatrix, Inc. amended Development and Commercialization Agreement (Cipla Agreement) with Cipla Technologies LLC valued at The Third Amendment terminates the Phase 2b clinical study of the Product and modifies responsibilit (effective 2024-01-06).

“On January 6, 2024 (the “Effective Date”), the Parties entered into the third amendment to the Cipla Agreement (the “Third Amendment”), which terminates the Phase 2b clinical study (the “Phase 2b Clinical Study”) of the Product and makes certain related modifications to the Cipla Agreement.”

Pulmatrix, Inc. reported the third fiscal quarter ended September 30, 2023 results: revenue $1.8 million.

“plans to pursue partnership opportunities to advance PUR1800 into a potential Phase 2 clinical trial. Third Quarter 2023 Financial Results Revenues decreased $0.1 million to $1.8 million for the three months ended September 30, 2023 compared to $1.9 million for the three months ended September 30, 2022. The decrease is related to the Company’s revenues recognized”

Pulmatrix, Inc. reported financial results for the second fiscal quarter ended June 30, 2023.

“On August 10, 2023, Pulmatrix, Inc. issued a press release announcing its financial results for the second fiscal quarter ended June 30, 2023 and provided a corporate update.”

Pulmatrix, Inc. shareholders approved Approval, on an advisory basis, of the compensation paid to the Company's named executive officers as set forth in the Proxy Statement. at the 2023-07-13 meeting.

“(3) Approval, on an advisory basis, of the compensation paid to the Company's named executive officers as set forth in the Proxy Statement (as defined below): For Against Withheld /Abstained Broker Non-Votes 603,083 565,062 124,075 889,699”

Pulmatrix, Inc. shareholders approved Ratification of the appointment of Marcum LLP as the Company's independent registered public accounting firm for the 2023 fiscal year. at the 2023-07-13 meeting.

“(2) Ratification of the appointment of Marcum LLP as the Company's independent registered public accounting firm for the 2023 fiscal year: For Against Withheld /Abstained Broker Non-Votes 1,860,275 251,489 70,155 0”

Pulmatrix, Inc. shareholders approved Election of two directors to serve as Class III directors on the Company's Board of Directors to serve until the Company's 2026 annual meeting of stockholders or until successors have been duly elected and qualified. at the 2023-07-13 meeting.

“Director For Against Withheld /Abstained Broker Non-Votes Michael J. Higgins 758,720 - 533,500 889,699 Anand Varadan 1,014,129 - 278,091 889,699”

Pulmatrix, Inc. reported the three months ended March 31, 2023 results: revenue $1.5 million.

“Revenues increased $0.3 million to $1.5 million for the three months ended March 31, 2023 compared to $1.2 million for the three months ended March 31, 2022.”

Pulmatrix, Inc. reported financial results for the first fiscal quarter ended March 31, 2023.

“On May 12, 2023, Pulmatrix, Inc. (the “Company”) issued a press release announcing its financial results for the first fiscal quarter ended March 31, 2023 and provided a corporate update. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.”

Pulmatrix, Inc. reported the year ended December 31, 2022 results: revenue $6.1 million.

“Revenue was $6.1 million for the year ended December 31, 2022”

Pulmatrix, Inc. reported the three months ended September 30, 2022 results: revenue $1,872, net income $(5,052), EPS $(1.45) per share.

“PULMATRIX, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) (in thousands, except share and per share data) Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Revenues $ 1,872 $ 1,069 $ 4,363 $ 4,713 Operating expenses: Research and development 5,287 4,026 13,773 12,423 General and administrative 1,685 1,656 5,212 4,837 Goodwill impairment - 3,577 - 3,577 Total operating expenses 6,972 9,259 18,985 20,837 Loss from operations (5,100 ) (8,190 ) (14,622 ) (16,124 ) Other income (expense), net: Interest income 102 1 118 6 Other (expense) income, net (54 ) 5 (116 ) (22 ) Total other income (expense), net 48 6 2 (16 ) Net loss $ (5,052 ) $ (8,184 ) $ (14,620 ) $ (16,140 ) Net loss per share attributable to common stockholders – basic and diluted $ (1.45 ) $ (2.91 ) $ (4.32 ) $ (6.08 )”

Peter Ludlum was appointed as Interim Chief Financial Officer at Pulmatrix, Inc..

“On April 14, 2022, the Board of Directors of Pulmatrix, Inc. (the “Company”) appointed Peter Ludlum as Interim Chief Financial Officer of the Company, effective as of April 18, 2022, to serve until a successor is chosen and qualified, or until his earlier resignation or removal.”

Anand Varadan was appointed as Director at Pulmatrix, Inc..

“On July 23, 2021, Anand Varadan was appointed to the board of directors of the Company, effective as of July 26, 2021, to serve as a Class III director”

Mark Iwicki resigned as Director at Pulmatrix, Inc..

“On July 23, 2021, Mark Iwicki resigned from the board of directors of Pulmatrix, Inc. (the “Company”).”